[{"iri":"<https://vivo.metabolomics.info/individual/pmid32551229>","pmid":"32551229","title":"Modeling of nitrogen fixation and polymer production in the heterotrophic diazotroph <i>Azotobacter vinelandii</i> DJ.","authors":["Karsten Zengler"],"published":"2020-12-01","citation":"Campos, DT., Zu√±iga, C., Passi, A., Del Toro, J., Tibocha-Bonilla, JD., Zepeda, A., Betenbaugh, MJ., Zengler, K. (2020). Modeling of nitrogen fixation and polymer production in the heterotrophic diazotroph <i>Azotobacter vinelandii</i> DJ. Metabolic Engineering Communications, 11, e00132. doi:10.1016/j.mec.2020.e00132"},{"iri":"<https://vivo.metabolomics.info/individual/pmid32516707>","pmid":"32516707","title":"Integrating untargeted metabolomics and targeted analysis for not from concentrate and from concentrate orange juices discrimination and authentication.","authors":["Lei Xu"],"published":"2020-11-01","citation":"Xu, L., Xu, Z., Kelly, S., Liao, X. (2020). Integrating untargeted metabolomics and targeted analysis for not from concentrate and from concentrate orange juices discrimination and authentication. Food Chemistry, 329, 127130. doi:10.1016/j.foodchem.2020.127130"},{"iri":"<https://vivo.metabolomics.info/individual/pmid32648916>","pmid":"32648916","title":"Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican.","authors":["Quiying Chen"],"published":"2020-10-05","citation":"Hong, CC., Tang, AT., Detter, MR., Choi, JP., Wang, R., Yang, X., Guerrero, AA., Wittig, CF., Hobson, N., Girard, R., Lightle, R., Moore, T., Shenkar, R., Polster, SP., Goddard, LM., Ren, AA., Leu, NA., Sterling, S., Yang, J., Li, L., Chen, M., Mericko-Ishizuka, P., Dow, LE., Watanabe, H., Schwaninger, M., Min, W., Marchuk, DA., Zheng, X., Awad, IA., Kahn, ML. (2020). Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. The Journal Of Experimental Medicine, 217(10). doi:10.1084/jem.20200140"},{"iri":"<https://vivo.metabolomics.info/individual/pmid32637455>","pmid":"32637455","title":"Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity.","authors":["Timothy Nichols"],"published":"2020-09-11","citation":"Pei, X., Shao, W., Xing, A., Askew, C., Chen, X., Cui, C., Abajas, YL., Gerber, DA., Merricks, EP., Nichols, TC., Li, W., Samulski, RJ., Li, C. (2020). Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity. Molecular Therapy. Methods & Clinical Development, 18, 259-268. doi:10.1016/j.omtm.2020.06.003"},{"iri":"<https://vivo.metabolomics.info/individual/pmid32602902>","pmid":"32602902","title":"Targeting leukocidin-mediated immune evasion protects mice from Staphylococcus aureus bacteremia.","authors":["Sergei Koralov"],"published":"2020-09-07","citation":"Tam, K., Lacey, KA., Devlin, JC., Coffre, M., Sommerfield, A., Chan, R., O'Malley, A., Koralov, SB., Loke, P., Torres, VJ. (2020). Targeting leukocidin-mediated immune evasion protects mice from Staphylococcus aureus bacteremia. The Journal Of Experimental Medicine, 217(9). doi:10.1084/jem.20190541"}]
